These data highlight RET and FGFR4 as therapeutic targets and suggest a potential role for the use of combined tyrosine kinase inhibitors in the management of inoperable medullary thyroid cancers [28]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.